Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | CCR6 | P51684 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 6Bio SCHEMBL21067440 | 1.00 | AGTR1 (0.48) | AGTR1IDO1TDO2LRRK2NTRK1 | |
| 6Bio SCHEMBL14088703 | 1.00 | AGTR1 (0.48) | AGTR1IDO1TDO2LRRK2NTRK1 | |
| SCHEMBL22300057 | 1.00 | AGTR1 (0.48) | AGTR1IDO1TDO2LRRK2NTRK1 | |
| 6Bio SCHEMBL30249771 | 1.00 | AGTR1 (0.48) | AGTR1IDO1TDO2LRRK2NTRK1 | |
| 6Bio SCHEMBL470802 | 1.00 | AGTR1 (0.48) | AGTR1IDO1TDO2LRRK2NTRK1 | |
| 6Bio SCHEMBL29975657 | 0.99 | AGTR1 (0.47) | AGTR1IDO1TDO2LRRK2NTRK1 | |
| 6Bio SCHEMBL27160645 | 0.99 | AGTR1 (0.47) | AGTR1IDO1TDO2LRRK2NTRK1 | |
| Indirubin 2 SCHEMBL22215161 | 0.91 | AGTR1 (0.49) | AGTR1IDO1TDO2LRRK2NTRK1 | |
| Indirubin 2 SCHEMBL30380962 | 0.91 | AGTR1 (0.49) | AGTR1IDO1TDO2LRRK2NTRK1 | |
| SCHEMBL3850179 | 0.91 | LRRK2 (0.50) | AGTR1IDO1TDO2LRRK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12053465-B2 | KCC2 expression enhancing compounds and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2024-08-06 | — | — | US | claimed |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-12-01 | — | — | US | claimed |
| US-11331313-B2 | KCC2 expression enhancing compounds and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-05-17 | — | — | US | claimed |
| EP-3964565-B1 | AN IN VITRO METHOD OF DIFFERENTIATING A HUMAN PLURIPOTENT STEM CELL POPULATION INTO A CARDIOMYOCYTE CELL POPULATION | NCARDIA B V (NL) | 2026-04-08 | — | — | EP | disclosed |
| US-20250340848-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | PEKING UNIVERSITY (CN) | 2025-11-06 | — | — | US | disclosed |
| EP-4602148-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | Peking University (CN) | 2025-08-20 | — | — | EP | disclosed |
| WO-2025069029-A1 | METHODS FOR REJUVENATING HUMAN CELLS | CENTARIX BIOTECH LTD (IL) | 2025-04-03 | — | — | WO | disclosed |
| US-20240350548-A1 | METHODS FOR GENERATION OF PODOCYTES FROM PLURIPOTENT STEM CELLS AND CELLS PRODUCED BY THE SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-10-24 | — | — | US | disclosed |
| US-12053465-B2 | KCC2 expression enhancing compounds and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240182867-A1 | CHEMICAL REPROGRAMMING OF HUMAN SOMATIC CELLS INTO PLURIPOTENT CELLS | PEKING UNIVERSITY (CN) | 2024-06-06 | — | — | US | disclosed |
| EP-3334820-B1 | INDUCED EXTENDED PLURIPOTENT STEM CELLS, METHODS OF MAKING AND USING | BEIHAO STEM CELL AND REGENERATIVE MEDICINE RES INSTITUTE CO LTD (CN) | 2024-05-15 | — | — | EP | disclosed |
| US-20150010515-A1 | MAMMALIAN NEURAL PLATE BORDER STEM CELLS CAPABLE OF FORMING NEURAL TUBE AND NEURAL CREST CELL LINEAGES INCLUDING CENTRAL AND PERIPHERAL NEURONS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-01-08 | — | — | US | disclosed |
| EP-2802332-A1 | MAMMALIAN NEURAL PLATE BORDER STEM CELLS CAPABLE OF FORMING NEURAL TUBE AND NEURAL CREST CELL LINEAGES INCLUDING CENTRAL AND PERIPHERAL NEURONS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-11-19 | — | — | EP | disclosed |
| WO-2014078414-A1 | CHEMICALLY DEFINED PRODUCTION OF CARDIOMYOCYTES FROM PLURIPOTENT STEM CELLS | WU JOSEPH (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20140134733-A1 | CHEMICALLY DEFINED PRODUCTION OF CARDIOMYOCYTES FROM PLURIPOTENT STEM CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2013104752-A1 | MAMMALIAN NEURAL PLATE BORDER STEM CELLS CAPABLE OF FORMING NEURAL TUBE AND NEURAL CREST CELL LINEAGES INCLUDING CENTRAL AND PERIPHERAL NEURONS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-07-18 | — | — | WO | disclosed |
| EP-2614829-A1 | Mammalian neural plate border stem cells capable of forming neural tube and neural crest cell lineages including central and peripheral neurons | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-07-17 | — | — | EP | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11331313-B2 | KCC2 expression enhancing compounds and uses thereof | MECP2, SLC1A2, GRIN2C | AGTR1 3439/4885IDO1 4516/4885TDO2 3205/4885 |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | MECP2, SLC1A2, GRIN2C | AGTR1 3439/4885IDO1 4516/4885TDO2 3205/4885 |
| US-12053465-B2 | KCC2 expression enhancing compounds and uses thereof | MECP2, SLC1A2, GRIN2C | AGTR1 3439/4885IDO1 4516/4885TDO2 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.